DE69905877T2 - Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen - Google Patents

Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen

Info

Publication number
DE69905877T2
DE69905877T2 DE69905877T DE69905877T DE69905877T2 DE 69905877 T2 DE69905877 T2 DE 69905877T2 DE 69905877 T DE69905877 T DE 69905877T DE 69905877 T DE69905877 T DE 69905877T DE 69905877 T2 DE69905877 T2 DE 69905877T2
Authority
DE
Germany
Prior art keywords
hormone receptor
thyroid hormone
fibrotic diseases
sup
treating fibrotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69905877T
Other languages
English (en)
Other versions
DE69905877D1 (de
Inventor
Edward Billingham
Katherine Fernihough
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
C/O ACORN CORPORATE FINANCE LTD., WILMSLOW, CHESHI
Original Assignee
ARTHROMICS PLC WILMSLOW
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9811784.9A external-priority patent/GB9811784D0/en
Application filed by ARTHROMICS PLC WILMSLOW filed Critical ARTHROMICS PLC WILMSLOW
Publication of DE69905877D1 publication Critical patent/DE69905877D1/de
Application granted granted Critical
Publication of DE69905877T2 publication Critical patent/DE69905877T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE69905877T 1998-06-02 1999-05-27 Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen Expired - Fee Related DE69905877T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9811784.9A GB9811784D0 (en) 1998-06-02 1998-06-02 Fibrotic disease
GBGB9827834.4A GB9827834D0 (en) 1998-06-02 1998-12-17 Fibrotic disease
PCT/GB1999/001684 WO1999062507A1 (en) 1998-06-02 1999-05-27 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease

Publications (2)

Publication Number Publication Date
DE69905877D1 DE69905877D1 (de) 2003-04-17
DE69905877T2 true DE69905877T2 (de) 2003-11-20

Family

ID=26313780

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69905877T Expired - Fee Related DE69905877T2 (de) 1998-06-02 1999-05-27 Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen

Country Status (8)

Country Link
US (5) US6348497B1 (de)
EP (1) EP1083891B1 (de)
JP (1) JP2002516855A (de)
AT (1) ATE234084T1 (de)
AU (1) AU4154799A (de)
DE (1) DE69905877T2 (de)
ES (1) ES2194466T3 (de)
WO (1) WO1999062507A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249519B (en) 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
RU2422450C2 (ru) * 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
GB0406378D0 (en) * 2004-03-22 2004-04-21 Karobio Ab Novel pharmaceutical compositions
US7932366B2 (en) 2004-07-07 2011-04-26 Biocon Limited Synthesis of azo bonded immunoregulatory compounds
EP1890768A2 (de) * 2005-05-26 2008-02-27 Metabasis Therapeutics, Inc. Neue phosphinsäurehaltige thyromimetika
JP5910099B2 (ja) 2012-01-18 2016-04-27 セイコーエプソン株式会社 干渉フィルター、光学モジュールおよび電子機器
AU2017363206A1 (en) 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
US11787828B2 (en) 2018-03-22 2023-10-17 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
DE2964097D1 (en) * 1978-09-08 1982-12-30 Ici Plc Anti-arthritic hydroxyacetic acid derivatives, pharmaceutical compositions thereof, and processes for their manufacture
GB2073177A (en) 1980-04-03 1981-10-14 Ici Ltd Benzaldehyde derivative
GB2073178B (en) * 1980-04-03 1984-01-25 Ici Ltd Dioxolane derivatives
CA2090407A1 (en) 1990-09-21 1992-03-22 Ronald M. Evans Functional antagonism between proto-oncoprotein c-jun and hormone receptors
EP0753147A1 (de) 1994-03-30 1997-01-15 Novartis AG Screeningsverfahren unter verwendung der rzr rezeptorfamilie
JPH10502454A (ja) 1994-07-01 1998-03-03 リガンド・ファーマシューティカルズ・インコーポレーテッド Ｎｕｃ阻害剤のスクリーニング
AU2332497A (en) * 1996-03-19 1997-10-10 Salk Institute For Biological Studies, The (in vitro) methods for identifying modulators of members of the steroid/thyroid superfamily of receptors

Also Published As

Publication number Publication date
US20020049254A1 (en) 2002-04-25
ATE234084T1 (de) 2003-03-15
US20070213402A1 (en) 2007-09-13
US20030018077A1 (en) 2003-01-23
EP1083891B1 (de) 2003-03-12
WO1999062507A1 (en) 1999-12-09
AU4154799A (en) 1999-12-20
DE69905877D1 (de) 2003-04-17
ES2194466T3 (es) 2003-11-16
US20040180963A1 (en) 2004-09-16
US6414026B1 (en) 2002-07-02
EP1083891A1 (de) 2001-03-21
JP2002516855A (ja) 2002-06-11
US6348497B1 (en) 2002-02-19

Similar Documents

Publication Publication Date Title
DE69905877T2 (de) Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
RU93058351A (ru) Замещенные 3-аминохинуклидины, фармацевтические композиции на его основе, способы лечения, способ получения, промежуточные соединения
DE69942610D1 (de) Die bindung von integrinen zu deren rezeptoren verhindernde verbindungen
EP0911331A3 (de) Substutierte Dibenzoxazepinverbindungen, pharmazeutische Zusammensetzungen, und Anwendungsmethoden
MA24832A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydropyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
DE69936848D1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
EP1491542A3 (de) Zwischenprodukte
WO2002055017A3 (en) Method of treating autoimmune diseases
EP0764886A3 (de) Naphthochinonderivate und diese enthaltendes elektrolichtempfindliches Material
HUP0003591A2 (hu) Az oppozíciós ellenálló rendellenesség kezelése
CY1105370T1 (el) Μεθοδος θepαπειας των κλιμακτηριακων διαταραχων στις εμμηνοπαυσιακες και μετεμμηνοπαυσιακες γυναικες
CA2015475A1 (en) Treating agent for osteoarthritis
BG104436A (en) The administration of macrolides for the treatment of cancer and macular degeneration
BG104357A (en) Derivatives of cyclopentene used as motiline receptor antagonists
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
GB2266665B (en) 5-HT1-like receptor agonist for rectal administration
ITBO950293A0 (it) Composto per il trattamento di escrementi animali
PT1066304E (pt) Antagonistas macrolidos de lhrh
EP1050303A3 (de) Methoden und Zusammenstellungen zur Behandlung von altersgebundenen Verhaltensstörungen von Haustieren
EP1253139A3 (de) Multioligoanilinierte Fullerene
EP0902025A3 (de) Benzothiophene zur Behandlung von Estrogen-abhängigen Erkrankungen
WO2000044408A3 (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: C/O ACORN CORPORATE FINANCE LTD., WILMSLOW, CHESHI

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee